Jasmeen Dara, MD, MS

10/2021 - Diversity, Equity, and Inclusion Champion Training, UCSF
06/2015 - Allergy & Immunology, Montefiore Medical Center/Albert Einstein College of Medicine
06/2013 - Pediatric Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine
06/2010 - Pediatrics, St. Christopher's Hospital for Children
MD, 05/2007 - , Tulane University School of Medicine
  1. Correction to: Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
  2. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
  3. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
  4. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome.
  5. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
  6. Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2).
  7. 2 Immunologic recovery and basis for infections in the pediatric hematopoietic stem cell transplant recipient.
  8. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients.
  9. A Pilot Trial of Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Pediatric Hematopoietic Stem Cell Transplant Patients.
  10. Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants.
  11. Early Outcome of a Phase I/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID).
  12. International Retrospective Study of Allogeneic Hematopoietic Cell Transplantation (HCT) for Activated Phosphoinositide 3-Kinase Delta (PI3K) Syndrome.
  13. Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants.
  14. Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis.
  15. Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency.
  16. The Impact of Total Body Irradiation-Based Regimens on Outcomes in Children and Young Adults with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
  17. Low Birth Weight in Human Immunodeficiency Virus-Exposed Uninfected Infants in Bronx, New York.
  18. Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.
  19. Optimal Antiretroviral Prophylaxis in Infants at High Risk of Acquiring HIV: A Systematic Review.
  20. Fulminant Sepsis Due to Granulibacter bethesdensis in a 4-Year-Old Boy With X-Linked Chronic Granulomatous Disease.
  21. Consanguineous Siblings with a Novel Mutation in Lipopolysaccharide-Responsive Beige-like Anchor protein (LRBA).
  22. Multivariable analysis to determine if HIV-1 Tat dicysteine motif is associated with neurodevelopmental delay in HIV-infected children in Malawi.
  23. Adherence to Therapy in Chronic Granulomatous Disease and Disease Outcomes: A Possibility for Development of New Therapeutic Delivery Devices.
  24. Clinical and Virological Characteristics Of HIV-Associated Lymphomas In Patients With Perinatally-Acquired HIV In The Era Of Antiretroviral Therapy.
  25. Microbiological and Genetic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated From Pediatric Patients.
  26. Resident comfort level after receiving child abuse training: a survey of pediatric chief residents.
  27. Myeloid differentiation primary response gene 88 (MyD88) deficiency in a large kindred.
  28. Pseudomonas Susceptibility in a Large MyD88 Deficient Kindred And The Use of IVIG Replacement Therapy.